tiprankstipranks
Trending News
More News >
Exicure Inc (XCUR)
NASDAQ:XCUR

Exicure (XCUR) Price & Analysis

Compare
973 Followers

XCUR Stock Chart & Stats


Financials

Options Prices

Currently, No data available
---

Ownership Overview

66.21%0.49%4.46%28.40%
66.21% Insiders
4.46% Other Institutional Investors
28.40% Public Companies and Individual Investors

XCUR FAQ

What was Exicure Inc’s price range in the past 12 months?
Exicure Inc lowest stock price was $1.44 and its highest was $36.00 in the past 12 months.
    What is Exicure Inc’s market cap?
    Exicure Inc’s market cap is $38.54M.
      When is Exicure Inc’s upcoming earnings report date?
      Exicure Inc’s upcoming earnings report date is Aug 19, 2025 which is in 46 days.
        How were Exicure Inc’s earnings last quarter?
        Exicure Inc released its earnings results on Jun 27, 2025. The company reported $0.487 earnings per share for the quarter, beating the consensus estimate of N/A by $0.487.
          Is Exicure Inc overvalued?
          According to Wall Street analysts Exicure Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Exicure Inc pay dividends?
            Exicure Inc does not currently pay dividends.
            What is Exicure Inc’s EPS estimate?
            Exicure Inc’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Exicure Inc have?
            Exicure Inc has 6,317,793 shares outstanding.
              What happened to Exicure Inc’s price movement after its last earnings report?
              Exicure Inc reported an EPS of $0.487 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 19.525%.
                Which hedge fund is a major shareholder of Exicure Inc?
                Currently, no hedge funds are holding shares in XCUR

                Company Description

                Exicure Inc

                Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
                Similar Stocks
                Company
                Price & Change
                Follow
                ESSA Pharma
                I-MAB
                Unicycive Therapeutics
                Caribou Biosciences
                Vigil Neuroscience Inc
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis